Big Pharma will get bigger, much bigger, over the next several years, with
the companies vying to grow their sales in a range of established and emerging
therapeutic areas, notably cancer and immunology.
Together, the top 10 drugmakers in 2024—as outlined in a recent report from
EvaluatePharma—will hold 35% of the total biopharma market share, or more than
$420 billion in sales that year.
Novartis is slated to lead the pack, trailed by Pfizer, Roche, Johnson
& Johnson and Sanofi in the top five. Among the top 10 drugmakers, EP
predicts AstraZeneca and Bristol-Myers Squibb will grow their sales the most
over the upcoming years, at 7% annually and 6% on average per year,
respectively.